Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats

Elena Ju Sudnikovich, Yuri Z. Maksimchik, Svetlana V. Zabrodskaya, Valeri L. Kubyshin, Elena A. Lapshina, Maria Bryszewska, Russel J Reiter, Ilya B. Zavodnik

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Enhanced oxidative stress and impairments in nitric oxide synthesis and bioavailability are of considerable importance in the pathogenesis of diabetic vascular diseases. The aim of the present work was to evaluate the metabolic effects of pharmacological doses of the melatonin, a known antioxidant, on streptozotocin-induced diabetic damage in rats. We investigated the indolamine's influence on the cellular redox-balance, nitric oxide (NO) level, and the activities of antioxidative defence enzymes, as well as the activities of enzymes involved in phase II detoxication and NADPH-generating pentose phosphate pathway. Blood glucose, glycated hemoglobin, bilirubin, as well as plasma alanine aminotransferase activities increased and body weight was reduced in rats with streptozotocin-induced (60 mg/kg, i.p.) diabetes (25 days). The NO level was markedly increased in diabetic plasma (by 50%) and aortic tissue (by 30%). The hyperglycemia resulted in reduced activities of glutathione peroxidase (by 25%), catalase (by 20%), glucose-6-phosphate dehydrogenase (by 55%) and transketolase (by 40%) in liver tissue of diabetic animals. Melatonin treatment (10 mg/kg, 18 days) did not influence the level of hyperglycemia or glycated hemoglobin and it had little effect on the activities of antioxidative enzymes. However, melatonin markedly reversed the activities of glucose-6-phosphate dehydrogenase and transketolase in liver tissue of diabetic rats. The most pronounced effect of the melatonin administration was the prevention of an increase in nitric oxide levels in blood plasma and aortic tissue during diabetes. In in vitro experiments, nitrosomelatonin formation in the presence of nitrosodonors was observed. This implies that melatonin might operate as an NO scavenger and carrier. Thus, melatonin treatment may have some beneficial effects in controlling diabetic vascular complications.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalEuropean Journal of Pharmacology
Volume569
Issue number3
DOIs
StatePublished - Aug 27 2007

Fingerprint

Experimental Diabetes Mellitus
Melatonin
Nitric Oxide
Transketolase
Diabetic Angiopathies
Glucosephosphate Dehydrogenase
Glycosylated Hemoglobin A
Streptozocin
Hyperglycemia
Enzymes
Pentose Phosphate Pathway
Liver
Glutathione Peroxidase
Alanine Transaminase
NADP
Bilirubin
Catalase
Biological Availability
Oxidation-Reduction
Glutathione

Keywords

  • Diabetes
  • Melatonin
  • Nitric oxide
  • Nitrosomelatonin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Sudnikovich, E. J., Maksimchik, Y. Z., Zabrodskaya, S. V., Kubyshin, V. L., Lapshina, E. A., Bryszewska, M., ... Zavodnik, I. B. (2007). Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. European Journal of Pharmacology, 569(3), 180-187. https://doi.org/10.1016/j.ejphar.2007.05.018

Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. / Sudnikovich, Elena Ju; Maksimchik, Yuri Z.; Zabrodskaya, Svetlana V.; Kubyshin, Valeri L.; Lapshina, Elena A.; Bryszewska, Maria; Reiter, Russel J; Zavodnik, Ilya B.

In: European Journal of Pharmacology, Vol. 569, No. 3, 27.08.2007, p. 180-187.

Research output: Contribution to journalArticle

Sudnikovich, EJ, Maksimchik, YZ, Zabrodskaya, SV, Kubyshin, VL, Lapshina, EA, Bryszewska, M, Reiter, RJ & Zavodnik, IB 2007, 'Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats', European Journal of Pharmacology, vol. 569, no. 3, pp. 180-187. https://doi.org/10.1016/j.ejphar.2007.05.018
Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, Kubyshin VL, Lapshina EA, Bryszewska M et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. European Journal of Pharmacology. 2007 Aug 27;569(3):180-187. https://doi.org/10.1016/j.ejphar.2007.05.018
Sudnikovich, Elena Ju ; Maksimchik, Yuri Z. ; Zabrodskaya, Svetlana V. ; Kubyshin, Valeri L. ; Lapshina, Elena A. ; Bryszewska, Maria ; Reiter, Russel J ; Zavodnik, Ilya B. / Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. In: European Journal of Pharmacology. 2007 ; Vol. 569, No. 3. pp. 180-187.
@article{fa7acb0ff62546f3adb38dda8cb0eb64,
title = "Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats",
abstract = "Enhanced oxidative stress and impairments in nitric oxide synthesis and bioavailability are of considerable importance in the pathogenesis of diabetic vascular diseases. The aim of the present work was to evaluate the metabolic effects of pharmacological doses of the melatonin, a known antioxidant, on streptozotocin-induced diabetic damage in rats. We investigated the indolamine's influence on the cellular redox-balance, nitric oxide (NO) level, and the activities of antioxidative defence enzymes, as well as the activities of enzymes involved in phase II detoxication and NADPH-generating pentose phosphate pathway. Blood glucose, glycated hemoglobin, bilirubin, as well as plasma alanine aminotransferase activities increased and body weight was reduced in rats with streptozotocin-induced (60 mg/kg, i.p.) diabetes (25 days). The NO level was markedly increased in diabetic plasma (by 50{\%}) and aortic tissue (by 30{\%}). The hyperglycemia resulted in reduced activities of glutathione peroxidase (by 25{\%}), catalase (by 20{\%}), glucose-6-phosphate dehydrogenase (by 55{\%}) and transketolase (by 40{\%}) in liver tissue of diabetic animals. Melatonin treatment (10 mg/kg, 18 days) did not influence the level of hyperglycemia or glycated hemoglobin and it had little effect on the activities of antioxidative enzymes. However, melatonin markedly reversed the activities of glucose-6-phosphate dehydrogenase and transketolase in liver tissue of diabetic rats. The most pronounced effect of the melatonin administration was the prevention of an increase in nitric oxide levels in blood plasma and aortic tissue during diabetes. In in vitro experiments, nitrosomelatonin formation in the presence of nitrosodonors was observed. This implies that melatonin might operate as an NO scavenger and carrier. Thus, melatonin treatment may have some beneficial effects in controlling diabetic vascular complications.",
keywords = "Diabetes, Melatonin, Nitric oxide, Nitrosomelatonin",
author = "Sudnikovich, {Elena Ju} and Maksimchik, {Yuri Z.} and Zabrodskaya, {Svetlana V.} and Kubyshin, {Valeri L.} and Lapshina, {Elena A.} and Maria Bryszewska and Reiter, {Russel J} and Zavodnik, {Ilya B.}",
year = "2007",
month = "8",
day = "27",
doi = "10.1016/j.ejphar.2007.05.018",
language = "English (US)",
volume = "569",
pages = "180--187",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats

AU - Sudnikovich, Elena Ju

AU - Maksimchik, Yuri Z.

AU - Zabrodskaya, Svetlana V.

AU - Kubyshin, Valeri L.

AU - Lapshina, Elena A.

AU - Bryszewska, Maria

AU - Reiter, Russel J

AU - Zavodnik, Ilya B.

PY - 2007/8/27

Y1 - 2007/8/27

N2 - Enhanced oxidative stress and impairments in nitric oxide synthesis and bioavailability are of considerable importance in the pathogenesis of diabetic vascular diseases. The aim of the present work was to evaluate the metabolic effects of pharmacological doses of the melatonin, a known antioxidant, on streptozotocin-induced diabetic damage in rats. We investigated the indolamine's influence on the cellular redox-balance, nitric oxide (NO) level, and the activities of antioxidative defence enzymes, as well as the activities of enzymes involved in phase II detoxication and NADPH-generating pentose phosphate pathway. Blood glucose, glycated hemoglobin, bilirubin, as well as plasma alanine aminotransferase activities increased and body weight was reduced in rats with streptozotocin-induced (60 mg/kg, i.p.) diabetes (25 days). The NO level was markedly increased in diabetic plasma (by 50%) and aortic tissue (by 30%). The hyperglycemia resulted in reduced activities of glutathione peroxidase (by 25%), catalase (by 20%), glucose-6-phosphate dehydrogenase (by 55%) and transketolase (by 40%) in liver tissue of diabetic animals. Melatonin treatment (10 mg/kg, 18 days) did not influence the level of hyperglycemia or glycated hemoglobin and it had little effect on the activities of antioxidative enzymes. However, melatonin markedly reversed the activities of glucose-6-phosphate dehydrogenase and transketolase in liver tissue of diabetic rats. The most pronounced effect of the melatonin administration was the prevention of an increase in nitric oxide levels in blood plasma and aortic tissue during diabetes. In in vitro experiments, nitrosomelatonin formation in the presence of nitrosodonors was observed. This implies that melatonin might operate as an NO scavenger and carrier. Thus, melatonin treatment may have some beneficial effects in controlling diabetic vascular complications.

AB - Enhanced oxidative stress and impairments in nitric oxide synthesis and bioavailability are of considerable importance in the pathogenesis of diabetic vascular diseases. The aim of the present work was to evaluate the metabolic effects of pharmacological doses of the melatonin, a known antioxidant, on streptozotocin-induced diabetic damage in rats. We investigated the indolamine's influence on the cellular redox-balance, nitric oxide (NO) level, and the activities of antioxidative defence enzymes, as well as the activities of enzymes involved in phase II detoxication and NADPH-generating pentose phosphate pathway. Blood glucose, glycated hemoglobin, bilirubin, as well as plasma alanine aminotransferase activities increased and body weight was reduced in rats with streptozotocin-induced (60 mg/kg, i.p.) diabetes (25 days). The NO level was markedly increased in diabetic plasma (by 50%) and aortic tissue (by 30%). The hyperglycemia resulted in reduced activities of glutathione peroxidase (by 25%), catalase (by 20%), glucose-6-phosphate dehydrogenase (by 55%) and transketolase (by 40%) in liver tissue of diabetic animals. Melatonin treatment (10 mg/kg, 18 days) did not influence the level of hyperglycemia or glycated hemoglobin and it had little effect on the activities of antioxidative enzymes. However, melatonin markedly reversed the activities of glucose-6-phosphate dehydrogenase and transketolase in liver tissue of diabetic rats. The most pronounced effect of the melatonin administration was the prevention of an increase in nitric oxide levels in blood plasma and aortic tissue during diabetes. In in vitro experiments, nitrosomelatonin formation in the presence of nitrosodonors was observed. This implies that melatonin might operate as an NO scavenger and carrier. Thus, melatonin treatment may have some beneficial effects in controlling diabetic vascular complications.

KW - Diabetes

KW - Melatonin

KW - Nitric oxide

KW - Nitrosomelatonin

UR - http://www.scopus.com/inward/record.url?scp=34547683153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547683153&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.05.018

DO - 10.1016/j.ejphar.2007.05.018

M3 - Article

VL - 569

SP - 180

EP - 187

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -